Is Neoadjuvant Therapy Needed in Patients with Resectable Pancreatic Cancer?

참고문헌 (10)

1. Ryan DP, "Pancreatic adenocarcinoma", N Engl J Med, 371, pp.1039~1049 (2014)
2. Groot VP, "Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma", Ann Surg, 267, pp.936~945 (2018)
3. Versteijne E, "Meta-analysis comparing upfront surgery with neoadjuvant treatment in patients with resectable or borderline resectable pancreatic cancer", Br J Surg, 105, pp.946~958 (2018)
4. Yoon Min Sung, "Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis", Gut and Liver, 16(1), pp.118~128 (2022), 거트앤리버 소화기연관학회협의회[DOI]
5. Conroy T, "FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer", N Engl J Med, 379, pp.2395~2406 (2018)
6. Mokdad AA, "Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer : a propensity score matched analysis", J Clin Oncol, 35, pp.515~522 (2017)
7. Versteijne E, "Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer : results of the Dutch randomized phase III PREOPANC trial", J Clin Oncol, 38, pp.1763~1773 (2020)
8. Janssen QP, "Total neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer(PREOPANC-2trial) : study protocol for a nationwide multicenter randomized controlled trial", BMC Cancer, 21, pp.300~ (2021)
9. Sohal DPS, "Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma : a phase 2 randomized clinical trial", JAMA Oncol, 7, pp.421~427 (2021)
10. Isaji S, "International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017", Pancreatology, 18, pp.2~11 (2018)

관련 논문AI추천